Kolon TissueGene, Inc. is a biopharmaceutical company, which engages in the development of clinical-stage cell therapies for osteoarthritis. It offers TG-C, a platform technology that consists of a combination of allogeneic primary cells combined with genetically modified cells. The company was founded by Kwan H. Lee on June 9, 1999 and is headquartered in Rockville, MD.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company